Cypherpunk Technologies Inc. Files 8-K

TL;DR

CYPH filed an 8-K on 12/30/25 covering Reg FD, other events, and financials.

AI Summary

Cypherpunk Technologies Inc. filed an 8-K on December 30, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as Leap Therapeutics, Inc. and Dekkun Corp, is incorporated in Delaware and has its principal executive offices in Cambridge, MA.

Why It Matters

This 8-K filing provides updates on Cypherpunk Technologies Inc.'s corporate activities and financial reporting, which are crucial for investors to understand the company's current status and regulatory compliance.

Risk Assessment

Risk Level: low — This filing is a routine 8-K reporting on standard corporate events and disclosures, not indicating any immediate significant risks.

Key Players & Entities

• Cypherpunk Technologies Inc. (company) — Registrant
• Leap Therapeutics, Inc. (company) — Former company name
• Dekkun Corp (company) — Former company name
• December 30, 2025 (date) — Date of earliest event reported
• Cambridge, MA (location) — Business address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share CYPH The Nasdaq Capital M
• $29 m — tional 56,418.09 ZEC, for approximately $29 million, at an average purchase price of
• $514.02 — illion, at an average purchase price of $514.02 per ZEC. The Company's aggregate ZEC ho
• $334.41 — chased at a cumulative average price of $334.41 per ZEC, and which represents an estima

Filing Documents

• tm2534480d2_8k.htm (8-K) — 27KB
• tm2534480d2_ex99-1.htm (EX-99.1) — 13KB
• tm2534480d2_8kimg001.jpg (GRAPHIC) — 5KB
• tm2534480d2_ex99-1img01.jpg (GRAPHIC) — 11KB
• 0001104659-25-125039.txt ( ) — 234KB
• cyph-20251230.xsd (EX-101.SCH) — 3KB
• cyph-20251230_lab.xml (EX-101.LAB) — 33KB
• cyph-20251230_pre.xml (EX-101.PRE) — 22KB
• tm2534480d2_8k_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On December 30, 2025, Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.), a Delaware corporation (the "Company"), issued a press release announcing the Company has purchased an additional 56,418.09 of Zcash ("ZEC"). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 7.01, including Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

01 Other Events

Item 8.01 Other Events. As disclosed above, on December 30, 2025, the Company issued a press release announcing it has purchased an additional 56,418.09 ZEC, for approximately $29 million, at an average purchase price of $514.02 per ZEC. The Company's aggregate ZEC holdings stand at 290,062.67, which were purchased at a cumulative average price of $334.41 per ZEC, and which represents an estimated 1.76% of the total circulating ZEC network supply.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of the Company, dated December 30, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CYPHERPUNK TECHNOLOGIES INC. Date: December 30, 2025 /s/ Douglas E. Onsi Douglas E. Onsi President & CEO

View Full Filing

View this 8-K filing on SEC EDGAR